Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.48 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21428781 | 0.92 | MAPK13 (0.42) | MAPK14MAPK13MAPK12MAPK11PTGS2 | |
| SCHEMBL15830857 | 0.83 | MAPK14 (0.44) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL21408420 | 0.83 | MAPK14 (0.39) | MAPK14MAPK13MAPK12MAPK11PTGS2 | |
| SCHEMBL19495419 | 0.79 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11PTGS2 | |
| SCHEMBL27595420 | 0.72 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11PTGS2 | |
| SCHEMBL18041502 | 0.71 | TGFBR1 (0.52) | — | |
| SCHEMBL15824679 | 0.71 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5686347 | 0.68 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL23410288 | 0.68 | PTGS2 (0.52) | MAPK14MAPK13MAPK12MAPK11PTGS2 | |
| SCHEMBL15830784 | 0.68 | KDM4C (0.46) | MAPK14MAPK13MAPK12MAPK11PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935271-B1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2935271-B1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9556179-B2 | Substituted imidazoles as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556179-B2 | Substituted imidazoles as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556179-B2 | Substituted imidazoles as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-03 | — | — | US | disclosed |
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-03 | — | — | US | disclosed |
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-03 | — | — | US | disclosed |
| EP-2935271-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014100533-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100533-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | MAPK14 218/4885MAPK13 209/4885MAPK12 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.